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Aim. Comparative study of the effect of chemotherapeutic drugs (doxorubicin, methotrexate and cisplatin) and
TGF-β on the human breast carcinoma MCF-7 cells, sensitive (wt) and resistant (DOX/R) to the doxorubicin ac-
tion. Methods. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the es-
timation of expression of mRNAs coding for the TGF-β isoforms (TGF-β1 and TGF-β2) and  the TGF-β type I and
II receptors (TβRI and TβRII). Trypan blue exclusion method was used for measuring cell number and cell viabi-
lity. Results. The MCF-7(DOX/R) cells were more refractory to the TGFβ1-dependent growth inhibition than the
MCF-7(wt) cells. The level of mRNAs coding for TGF-β  and its receptors was higher in the untreated MCF-7
(DOX/R) cells comparing to the MCF-7(wt) cells. The expression of mRNA coding for TβRII was decreased in
both cell lines treated with doxorubicin, methotrexate and cisplatin, while the down-regulation of mRNA coding
for TβRI was revealed only in the  MCF-7(DOX/R) cells upon the treatment with doxorubicin and methotrexate.
Conclusions. The differential effects of studied anticancer drugs and TGF-β on the doxorubicin-sensitive and -re-
sistant cells have been demonstrated. The elucidation of the molecular mechanisms of escape of the MCF-7
(DOX/R) cells from the growth inhibition by TGF-β requires further investigation. 
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Introduction. Chemotherapy is a major tool in the treat-
ment of breast cancer. However, the main problem hin-
dering the success of chemotherapy is the development
of acquired tumor drug resistance during the treatment.
Although the most common chemotherapeutic drugs
used for the breast cancer treatment cause DNA dama-
ge and induce apoptosis, they exert the cell killing ef-
fects through different molecular mechanisms. The bio-
logical effects displayed by doxorubicin that may be
responsible for the inhibition of tumor cell growth in-
volve the covalent DNA binding and DNA cross-lin-
king, topoisomerase II inhibition, arrest of tumor cell
cycle progression in G2 phase, induction of apoptosis
and free radicals formation [1, 2]. The alkylating agent
cisplatin binds to DNA bases causing intra- and inter-
strand cross-links and breaks in DNA strands, and thus, 
interfering with the DNA replication [3]. The antimeta- 
bolite methotrexate inhibits the enzyme dihydrofolate
reductase preventing normal synthesis of the nucleosi-
de triphosphates [4]. 
The tumor cells, resistant to a single chemothera-
peutic agent, can also become cross-resistant to several
other anti-cancer drugs due to the development of their
multi-drug resistance. Such resistance was shown to be
associated with numerous mechanisms: 1) decreased
drug accumulation and/or altered intracellular distribu- 
tion of drugs; 2) increased activity of the cell detoxifica-
tion systems; 3) alterations in the cell cycle and signal
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transduction pathways; 4) increased repair of DNA
damage and high anti-apoptotic potential of the tumor
cells [5–7].
The multi-drug resistance in the MCF-7(DOX/R)
cells was shown to be associated with various mecha-
nisms including the over-expression of P-glycoprotein, 
glutathione S-transferase and glutathione peroxidase,
the loss of estrogen responsiveness, the DNA hypo-
methylation (loss of cytosine methylation of the MDR1,
GSTpi and MGMT chemoresistance related genes) [6,
8], and the changes in the expression of several cell cyc-
le regulators (decreased Ki-67, cyclin D1 and pRb and
increased p21 expression) [9]. The elucidation of novel 
mechanisms of drug resistance and further develop-
ment of the ways of overcoming such resistance or pre-
venting its occurrence might increase the efficiency of
treatment of cancer patients. 
TGF-β belongs to the most perspective molecular
markers which have both prognostic and predictive sig- 
nificance in the breast cancer [10, 11]. This cytokine is
involved either in the regulation of cell proliferation,
differentiation, apoptosis or in the intracellular and ex-
tracellular processes which contribute to the tumor pro- 
gression (e. g. pro-tumorigenic effects on the vascular,
immune and fibroblastic cells) [10]. However, TGF-β
may induce the entirely different cellular responses,
depending on the cell type and the stimulation context, 
under both physiological and pathological conditions
[12]. An alteration in the expression of the TGF-β re-
ceptors and the post-receptor signal transduction pro-
teins may play a critical role in the rendering malignant
cells resistant to TGF-β [13–15]. 
Thus, there are multiple etiologies of the develop-
ment of drug resistance, and the role of TGF-β  regula-
tory system in the refractoriness of cancer cells to che-
motherapeutic agents is not fully understood. In the pre-
sent study, we have compared the effect of some of the
most common drugs used for breast cancer treatment
(doxorubicin, cisplatin and methotrexate) on the expres- 
sion of mRNAs coding for TGF-β and its receptors in
the doxorubicin-sensitive and the doxorubicin-resis-
tant human breast cancer cells. Besides, we have com-
pared the inhibiting effect of TGF-β on cell growth in 
the  tested cell sub-lines in order to check if the tumor 
cross-refractoriness to both doxorubicin and TGF-β
may exist. 
Materials and methods. Cell lines and culture con- 
ditions. Human breast carcinoma MCF-7 cells differing 
in their sensitivity to doxorubicin (sensitive MCF-7
(wt) and resistant (MCF-7(DOX/R) cells) were obtai-
ned from Cell Collection of the Institute of Oncology
(«Gliwice», Poland). The cells were cultured in the Dul-
becco’s modified Eagle’s medium (DMEM, «Sigma
Chemical Co.», USA) supplemented with 10 % heat-in-
activated fetal calf serum (FCS, «Sigma Chemical Co.»)
and 50 µg/ml gentamycin («Sigma Chemical Co.»).
The cultured cells were maintained at 37 oC in a humidi-
fied (100 %) incubator with 5 % CO2. 
Drug treatment. Doxorubicin and cisplatin were pur-
chased from «Ebewe» (Austria), and methotrexate –
from «Leberle» (USA). Each drug was added 24 h after
cell plating and each sample was incubated for 24 h with
the chemotherapeutic drug of appropriate concentration.
Transforming growth factor β1 was purchased from «R
& D Systems, Inc.» (USA). 
Measuring cell number and viability. The effect of
TGF-β1 and doxorubicin on cell growth and viability
was determined using trypan blue (0.1 % (w/v)) exclu-
sion method. The numbers of dead (stained) cells and
alive (unstained) cells were counted in the hemocyto-
meter chamber under the light microscope.
Isolation of total RNA and RT-PCR assay. The amount
of mRNAs coding for TGF-β1, TGFβ2, TβRI and TβRII
was determined by the reverse transcriptase-polyme-
rase chain reaction (RT-PCR). Total RNA was isolated
from the cells by Trizol Reagent («Life Technologies,
Inc.», USA) following  the  standard protocol, and quan-
tified spectrophotometrically. The first-strand cDNA
synthesis and amplification of the specific DNA sequen- 
ce were performed according to the manufacturer’s ins-
tructions («RevertAidTM First Strand cDNA Synthesis
Kit», «Fermentas», Lithuania). Briefly, 5 µg of total RNA 
was used for cDNA synthesis using 1 µl of oligo(dT)
primer (0.5 µg/µl) in the presence of 1 µl (200 U) of Mo- 
loney murine leukemia virus reverse transcriptase. The
obtained cDNAs were used in RT-PCR analysis as des- 
cribed previously [16]. The cDNA encoding TGF-β1
was amplified for 30 cycles (94 °C for 1 min, 65 °C for
1 min, and 72 °C for 1 min). The cDNA encoding TGF-
β2 was amplified for 33 cycles (94 °C for 1 min, 55 °C
for 1 min, and 72 °C for 1 min). The cDNAs encoding
TβRI and TβRII were amplified for 30 cycles (94 °C for
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1 min, 55 °C for 1 min, and 72 °C for 1 min). The cDNA
encoding β-actin was amplified for 25 cycles (94 °C for
1 min, 65 °C for 1 min, and 72 °C for 1 min). The expec-
ted sizes of the PCR products and the primer sequences
used were as follows:
forward primer 5'-TGAACCGGCCTTTCCTGCT
TCTCATG-3' and reverse primer 5'-GCGGAAGTC
AATGTACAGCTGCCGC-3', 152 bp; TGF-β1;
forward primer 5'-ACAGGAACCTGGGATTTA
AAATAAG-3' and reverse primer 5'-TTTCTGATCA
CCACTGGTATATGTG-3', 152 bp; TGF-β2;
forward primer 5'-TGAACAGAAGTTAAGGCC
AAATATC-3' and reverse primer 5'-CAGGCAAAGC
TGTAGAATTACATTT-3', 192 bp; TβRI;
forward primer 5'-CGGTTAATAACGACATGA
TAGTCAC-3' and reverse primer 5'-TCATGGCAAA
CTGTCTCTAGTGTTA-3', 217 bp; TβRII;
forward primer 5'-TCACCCACACTGTGCCCAT
CTA-3' and reverse primer 5'-CAGCGGAACCGCTC
ATTGCCAA-3', 295 bp; β-actin. 
β-Actin was used as an internal control for normali-
zing the amount of sample loading. 
The reaction products were analyzed by electropho-
resis in 2 % agarose gels and visualized by ethidium bro- 
mide staining of DNA. Gels were examined under UV-
light using the transilluminator Macro Vue UV-20 («Ho- 
effer Pharmacia Biotech Inc.», USA) and photogra-
phed using the Olympus C-4000 digital camera. Semi-
quantitation of the ethidium bromide stained DNA bands
was performed using the Gel-Pro Analyzer v3.1.00.00
program («Media Cybernetics, L. P.», USA).
Statistical analysis. The experiments were repeated 
3 times and significance of difference was assessed by
Student’s t-test. The level of significance was set at 0.05.
Results and discussion. Our previous study has
shown that the MCF-7(DOX/R) cells, comparing to the 
MCF-7(wt) cells, are more refractory to the cytotoxic
and cytostatic effects of the studied anticancer drugs
[17] and ionizing radiation [18]. We also have revealed
a higher DNA repair potential in the MCF-7 (DOX/R)
cells than in the MCF-7(wt) cells [19]. The treatment of 
the MCF-7 and T47D cell lines of human breast carci-
noma with doxorubicin (1–100 µg/ml) induced a secre- 
tion of TGF-β1 by both cell lines in  a dose-dependent 
manner [20]. An elevated level of TGF-β1 was detected
in the blood plasma of breast [21], lung [22], colorectal
[23, 24] cancer patients and metastatic patients with pro- 
state cancer [25]. 
In order to compare  the  sensitivity of studied cells to
TGF-β1, the cells were incubated in the absence (control) 
or presence of TGF-β1 (10 ng/ml) for 24 and 48 h. We
found that the MCF-7(wt) cells were more sensitive to
the growth inhibition by  the  exogenous TGF-β1 action
than the MCF-7(DOX/R) cells (Table). The TGF-β1 in-
hibited growth and caused cell death (16.5 ± 2.3 %) of
the MCF-7(wt) cells (p < 0.001) after a 48 h incubation,
whereas in the similarly treated MCF-7 (DOX/R) cells   
no statistically significant changes were observed in the
growth inhibition comparing to the control (untreated)
cells of that sub-line. Doxorubicin (5 µg/ml) was used
as a positive control of the drug effect on the cell growth
and viability of the sensitive and resistant sub-lines of
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Factor
MCF-7(wt) MCF-7(DOX/R)
Cell number, % of control Cell viability, % of dead cells Cell number, % of control Cell viability, % of dead cells
Time of incubation, 24 h
Control 100.0 ± 2.4 2.0 ± 0.3 100.0 ± 3.2 3.0 ± 0.5
Doxorubicin 24.0 ± 2.5** 3.0 ± 0.6 95.0 ± 2.8 2.0 ± 0.5
TGF-β1 83.0 ± 2.2** 7.0 ± 0.5** 89.2 ± 4.3 2.0 ± 0.3
Time of incubation, 48 h
Control 100.0 ± 1.5 4.0 ± 0.8 100.0 ± 1.6 3.0 ± 0.9
Doxorubicin 13.0 ± 1.5** 7.0 ± 0.9* 90.0 ± 4.5* 5.0 ± 0.5
TGF-β1 75.0 ± 3.3** 16.5 ± 2.3** 95.0 ± 4.4 5.1 ± 0.7
*p < 0.05; **p < 0.001 (in treated versus the respective control (untreated) cells).
The effect of TGF-β1 (10 ng/ml) and doxorubicin (5 µg/ml) treatment on growth and viability of MCF-7(wt) and MCF-7 (DOX/R) cells 
the MCF-7 cells (Table). It is known that during the ear-
ly phase of epithelial tumorigenesis, TGF-β  inhibits the 
primary tumor development and growth by inducing
the cell cycle arrest and apoptosis.  At the  late stages of
tumor progression when the tumor cells become resis-
tant to the growth inhibition by TGF-β due to inactiva-
tion of the TGF-β signaling pathway or aberrant regula- 
tion of the cell cycle, TGF-β exhibits a pro-metastatic
role [26]. Earlier it has been found that the cisplatin-re-
sistant sub-line of murine leukemia L1210 cells posses- 
ses  a cross-resistance to TGF-β1 and  the  mechanism of 
drug resistance, based on the involvement of TGF-β1,
has been proposed [27].   
We also studied whether the above mentioned anti-
cancer drugs can alter the expression of mRNAs for
TGF-β and its receptors in the MCF-7(wt) and the
MCF-7(DOX/R) cells. The cells of both sub-lines were
exposed to different doses of the anticancer drugs, do-
xorubicin (5 µg/ml), methotrexate (25 µg/ml) and cis-
platin (10 µg/ml) at 24 h exposure. When using β-actin
as an internal control for normalizing the amount of
sample loading, we found that the levels of mRNAs co- 
ding for TGF-β1, TGF-β2, TβRI and TβRII, were higher
in the untreated MCF-7(DOX/R) cells comparing to the
untreated MCF-7(wt) cells (Fig. 1 and Fig. 2). It was re- 
ported that the expression of mRNAs coding for TGF-
β2 and TGF-β receptors (TβRI and TβRII) was higher in
most malignant tumor cells, for example, in the breast
cancer cells of Hs578T line [28]. Thus, we hypothesize
that the genes of the TGF-β regulatory system, the ex-
pression of which is higher in the doxorubicin-resis-
tant cancer cell line (MCF-7(DOX/R)), may be respon-
sible for the observed chemoresistance via their protein 
products.
The results presented in Fig. 1 and Fig. 2, A, show
that under the doxorubicin action there was no statisti-
cally significant increase in the expression of the TGF-
β1 mRNA in both cell lines tested, whereas a decrease in 
the expression of the TGF-β2 mRNA was revealed in
the MCF-7(wt) and MCF-7(DOX/R) cells (1.4 and 2.3
fold, correspondingly) (Fig. 2, B). Methotrexate and cis-
platin did not affect the expression of mRNAs coding
for TGF-β1 ligand in both studied cancer cell lines (Fig.
2, A). We found an increase in the TGF-β2 mRNA ex-
pression in the MCF-7(wt) cells treated with methotre-
xate and in the MCF-7(DOX/R) cells treated with me-
thotrexate and cisplatin (Fig. 2, B).
TGF-βs elicit their effects via binding with recep-
tors on the cellular surface [10]. TβRI and TβRII form a
heteromeric receptor complex. The direct involvement
of both TβRI and TβRII in conferring TGF-βs effects
indicates that the loss of either of the functional recep-
tors would contribute to the failure to respond to auto-
crine and exogenous TGF-β [13, 14, 29]. It has been
shown that the mutational inactivation of TβRII occurs
frequently in a subset of the microsatellite unstable co-
lon cancers [30]. The inactivation of TβRII has also been 
described in the non-small cell lung adenocarcinomas
and the small cell lung carcinomas [31]. Several studies 
describe the mutations in TβRI and TβRII in the adeno-
mas and gliomas [32–34] as well as a correlation bet-
ween higher expression of TβRI and TβRII and more ag-
gressive glioma cell lines and tumors [35, 36]. 
The treatment of cells with doxorubicin and metho- 
trexate decreased the production of mRNA coding for
TβRI (2.0 and 1.4 fold, correspondingly) in the doxoru- 
bicin-resistant sub-line, while no statistically signifi-
cant changes in the level of TβRI mRNA were found in
the doxorubicin-sensitive sub-line under the same con-
ditions (Fig. 2, C). A two-fold increase of mRNA coding 
for TβRI was detected in the MCF-7(wt) cells treated
with cisplatin. At the moment, the reasons for such dy-
namics in the TβRI expression in MCF-7(wt) cells un-
der cisplatin treatment are unknown, and additional stu-
dies are needed to get a support for such explanation of
the detected differences. 
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Fig. 1. Representative RT-PCR analysis of cDNA corresponding
mRNA coding for TGF-β1 (A), TGF-β2 (B), TβRI (C), TβRII (D) and
β-actin (E) in MCF-7(wt) cells (1–4) and MCF-7(DOX/R) cells (5–8):
1, 5 – untreated cells; 2, 6 – doxorubicin (5 µg/ml); 3, 7 – methotrexate
(25 µg/ml); 4, 8 – cisplatin (10 µg/ml)
We also revealed a decreased expression of the
mRNA coding for TβRII in both studied cell sub-lines
under the action of anticancer drugs used. The most pro-
minent effect on the MCF-7(wt) cells was found for the
cisplatin action, while in MCF-7(DOX/R) cells – for
the doxorubicin action (Fig. 2, D). Earlier, it has been
established that anticancer drugs doxorubicin and cis-
platin decrease the expression of the mRNA coding for
TβRII in the human lung adenocarcinoma A549 cells,
and cause the changes in the post-receptor Smad-depen-
dent TGF-β1 signaling pathway [37]. 
In summary, we have got the evidence that the resis-
tance of the human breast cancinoma cells to doxorubi-
cin is a multi-factorial phenomenon. The multi-facto-
rial resistance to doxorubicin might explain the cross-
resistance of MCF-7(DOX/R) cells to other compounds
(methotrexate and cisplatin) which are even not structu-
rally related. 
The following conclusions can be suggested taking
into account the results obtained: 1) tumor cell refracto- 
riness of the MCF-7(DOX/R) cells to both doxorubicin
and TGF-β1 was found; 2) the studied anticancer drugs
(doxorubicin, methotrexate and cisplatin) can inhibit
the transduction of TGF-β regulatory signals in both
cell sub-lines tested owing to the violation of the corres-
ponding signal pathway at different levels, particularly
by decreasing the expression of the mRNA coding for
TβRII; 3) TGF-β  might affect the response of the breast 
cancer cells to the anticancer drugs, thereby, allowing
for a possibility of chemotherapeutic modulation.
Âïëèâ ïðî òè ïóõ ëèí íèõ ïðå ïà ðàò³â íà êë³òèíè êàð öè íî ìè 
ìî ëî÷ íî¿ çà ëî çè, ÷óò ëèâ³ òà ñò³éê³ äî äîê ñî ðóá³öèíó: 
åêñïðåñ³ÿ ìÐÍÊ ÒÔÐ-β ³ éîãî ðå öåï òîð³â
². Â. ×îð íà, Î. Â. Ôå äî ðåí êî, Ð. Ñ. Ñòîé êà
Ðå çþ ìå
Ìåòà. Ïîð³âíÿëü íèé àíàë³ç âïëè âó ïðî òè ïóõ ëèí íèõ ïðå ïà ðàò³â
(äîê ñî ðóá³öèíó, ìå òîò ðåê ñà òó ³ öèñ ïëà òè íó) òà TÔÐ-β íà êë³òè- 
íè êàð öè íî ìè ìî ëî÷ íî¿ çà ëî çè ëþ äè íè ë³í³¿ MCF-7, ÷óò ëèâ³ (wt) ³
ñò³éê³ (DOX/R) äî ä³¿ äîê ñî ðóá³öèíó. Ìå òî äè. Íàï³âê³ëüê³ñíó ïî-
ë³ìå ðàç íó ëàí öþ ãî âó ðå àêö³þ (ÏËÐ) âè êî ðèñ òî âó âà ëè äëÿ âèç íà -
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Fig. 2. Densitometric measurement of cDNA corresponding mRNA coding for TGF-β1 (A), TGF-β2 (B), TβRI (C) and TβRII (D) mRNAs nor-
malized against β-actin mRNA levels in MCF-7(wt -yellow) (1–4) and MCF-7(DOX/R- blue) (5–8) cells: 1, 5 – untreated cells; 2, 6 – doxorubicin
(5 µg/ml); 3, 7 – methotrexate (25 µg/ml); 4, 8 – cisplatin (10 µg/ml); ×p < 0.05; ××p < 0.01 (in MCF-7(DOX/R) versus MCF-7(wt) cells); *p < 0.05;
**p < 0.01 (in cells treated by anticancer drugs versus the respective control (untreated) cells)
÷åí íÿ åêñïðåñ³¿ ìÐÍÊ ³çî ôîðì TÔÐ-β (TÔÐ-β1 ³ TÔÐ-β2) òà ðå öåï -
òîð³â TÔÐ-β I ³ II òèïó (TβRI ³ TβRII). Ìå òîä âè ëó ÷åí íÿ òðè ïà íî-
âîãî ñèíü î ãî çà ñòî ñî âà íî äëÿ âè ÿâ ëåí íÿ ê³ëüêîñò³ ³ æèòòºçäàò -
íîñò³ êë³òèí. Ðå çóëü òà òè. Êë³òè íàì ë³í³¿ MCF-7(DOX/R) ïðè òà-
ìàííà á³ëüøà ñò³éê³ñòü äî ð³ñò³íã³áó âàëü íî¿ ä³¿ ÒÔÐ-β1, í³æ êë³-
òè íàì ë³í³¿ MCF-7(wt). Ð³âåíü ìÐÍÊ ÒÔÐ-β ³ éîãî ðå öåï òîð³â âè-
ÿâèâ ñÿ âè ùèì ó íå îá ðîá ëå íèõ êë³òè íàõ MCF-7(DOX/R) ïîð³âíÿ íî
ç êë³òè íà ìè MCF-7(wt). Åêñïðåñ³ÿ ìÐÍÊ TβRII çíè æó âà ëà ñÿ â îáîõ
êë³òèí íèõ ë³í³ÿõ, îá ðîá ëå íèõ äîê ñî ðóá³öè íîì, ìå òîò ðåê ñà òîì ³
öèñ ïëà òè íîì, òîä³ ÿê ïàä³ííÿ ð³âíÿ ìÐÍÊ TβRI ñïîñ òåð³ãàëè ëè-
øå â êë³òè íàõ MCF-7(DOX/R), ï³ääà íèõ âïëè âó äîê ñî ðóá³öèíó ³ ìå-
òîò ðåê ñà òó. Âèñ íîâ êè. Âñòà íîâ ëå íî â³äì³ííîñò³ â ä³¿ äîñë³äæå -
íèõ ïðî òè ïóõ ëèí íèõ ïðå ïà ðàò³â ³ TÔÐ-β íà äîê ñî ðóá³öèí-÷óò ëèâ³
³ -ñò³éê³ êë³òèíè. Ïî äàëüø³ äîñë³äæåí íÿ íå îáõ³äí³  äëÿ ç’ÿ ñó âàí íÿ 
ìî ëå êó ëÿð íèõ ìå õàí³çì³â óíèê íåí íÿ ð³ñò³íã³áó âàëü íî¿ ä³¿ ÒÔÐ-β
êë³òè íà ìè ë³í³¿ MCF-7(DOX/R).
Êëþ ÷îâ³ ñëî âà: MCF-7, ÒÔÐ-β, äîê ñî ðóá³öèí, ìå òîò ðåê ñàò,
öèñ ïëà òèí, ðå çèñ òåíòí³ñòü.
Âëè ÿ íèå ïðî òè âî î ïó õî ëå âûõ ïðå ïà ðà òîâ íà êëåò êè 
êàð öè íî ìû ìî ëî÷ íîé æå ëå çû, ÷ó âñòâè òåëü íûå è óñòîé ÷è âûå 
ê äîê ñî ðó áè öè íó: ýêñ ïðåñ ñèÿ ìÐÍÊ ÒÔÐ-β è åãî ðå öåï òî ðîâ
È. Â. ×åð íàÿ, À. Â. Ôå äî ðåí êî, Ð. Ñ. Ñòîé êà
Ðå çþ ìå
Öåëü. Ñðàâ íè òåëü íûé àíà ëèç âëè ÿ íèÿ ïðî òè âî î ïó õî ëå âûõ ïðå ïà -
ðà òîâ (äîê ñî ðó áè öè íà, ìå òîò ðåê ñà òà è öèñ ïëà òè íà), à òàê æå
TÔÐ-β íà êëåò êè êàð öè íî ìû ìî ëî÷ íîé æå ëå çû ÷å ëî âå êà ëè íèè
MCF-7, ÷ó âñòâè òåëü íûå (wt) è óñòîé ÷è âûå (DOX/R) ê äå éñòâèþ
äîêñî ðó áè öè íà. Ìå òî äû. Ïî ëó êî ëè ÷åñ òâåí íóþ ïî ëè ìå ðàç íóþ öåï- 
íóþ ðå àê öèþ (ÏÖÐ) èñ ïîëü çî âà ëè äëÿ îïðå äå ëå íèÿ ýêñ ïðåñ ñèè
ìÐÍÊ èçî ôîðì TÔÐ-β (TÔÐ-β1 è TÔÐ-β2) è ðå öåï òî ðîâ ÒÔÐ-β I è
II òèïà (TβRI è TβRII). Ìå òîä èñ êëþ ÷å íèÿ òðè ïà íî âî ãî ñè íå ãî
ïðè ìå íåí äëÿ óñòà íîâ ëå íèÿ êî ëè ÷åñ òâà è æèç íåñ ïî ñîá íîñ òè êëå -
òîê. Ðå çóëü òà òû. Êëåò êàì ëè íèè MCF-7(DOX/R) ñâî éñòâåí íà
áîëüøàÿ óñòîé ÷è âîñòü ê ðîñ òèí ãè áè ðó þ ùå ìó äå éñòâèþ ÒÔÐ-β1,
÷åì êëåò êàì ëè íèè MCF-7(wt). Óðî âåíü ìÐÍÊ ÒÔÐ-β è åãî ðå öåï -
òî ðîâ îêà çàë ñÿ âûøå â íå îá ðà áî òàí íûõ êëåò êàõ MCF-7(DOX/R)
ïî ñðàâ íå íèþ ñ êëåò êà ìè MCF-7(wt). Ýêñïðåñ ñèÿ ìÐÍÊ TβRII ñíè- 
æà ëàñü â îá å èõ êëå òî÷ íûõ ëè íè ÿõ, îá ðà áî òàí íûõ äîê ñî ðó áè öè -
íîì, ìå òîò ðåê ñà òîì è öèñ ïëà òè íîì, òîã äà êàê ïà äå íèå óðîâ íÿ
ìÐÍÊ TβRI âû ÿâ ëå íî òîëü êî â êëåò êàõ MCF-7(DOX/R), ïîä âåðã-
øèõ ñÿ âëè ÿ íèþ äîê ñî ðó áè öè íà è ìå òîò ðåê ñà òà. Âû âî äû. Óñòà -
íîâ ëå íû ðàç ëè ÷èÿ â äå éñòâèè èç ó÷åí íûõ ïðî òè âî î ïó õî ëå âûõ ïðå -
ïà ðà òîâ è TÔÐ-β íà äîê ñî ðó áè öèí-÷ó âñòâè òåëü íûå è -óñòîé-
÷è âûå êëåò êè.  Äàëü íåé øèå èñ ñëå äî âà íèÿ íå îá õî äè ìû äëÿ âû ÿñ íå -
íèÿ ìî ëå êó ëÿð íûõ ìå õà íèç ìîâ èç áå æà íèÿ ðîñ òèí ãè áè ðó þ ùå ãî
äå éñòâèÿ ÒÔÐ-β êëåò êà ìè ëè íèè MCF-7(DOX/R). 
Êëþ ÷å âûå ñëî âà: MCF-7, ÒÔÐ-β, äîê ñî ðó áè öèí, ìå òîò ðåê ñàò, 
öèñ ïëà òèí, ðå çèñ òåí òíîñòü.  
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